Tartarate resistant acid phosphatase as a marker in osteoporosis and bone malignancy

Rajeshwari, Benedicta D'Souza, Vivian D'Souza

Research output: Contribution to journalArticle

Abstract

Non prostatic tartarate resistant acid phosphatase(TRACP) is present in bone resorbing osteoclasts. Matrix degradation products together with TRACP are released from the osteoclasts into the blood circulation. Therefore this study is carried out to study TRACP as a marker for osteoporosis and bone malignancy. A total of 75 subjects were included in this study. They were divided into 3 groups. Group I included 25 diagnosed cases of malignant bone tumors between the age group 20 to 70 years of both sexes. Group II included 25 cases of osteoporosis and group III, the control group, included 25 healthy individuals of the same age groups and sexes. TRACP was estimated in the serum of all the subjects. TRACP levels were highly increased in both the osteoporosis and bone malignancy groups (p<0.001). Therefore TRACP can be considered as a marker for bone resorption in osteoporosis and bone malignancy.

Original languageEnglish
JournalInternational Journal of Pharma and Bio Sciences
Volume5
Issue number3
Publication statusPublished - 01-01-2014
Externally publishedYes

Fingerprint

Acid Phosphatase
Osteoporosis
Bone
Bone and Bones
Neoplasms
Osteoclasts
Age Groups
Blood Circulation
Hemodynamics
Bone Resorption
Tumors
Degradation
Control Groups
Serum

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

@article{c559512390e94eedbc6ba087fb0c8365,
title = "Tartarate resistant acid phosphatase as a marker in osteoporosis and bone malignancy",
abstract = "Non prostatic tartarate resistant acid phosphatase(TRACP) is present in bone resorbing osteoclasts. Matrix degradation products together with TRACP are released from the osteoclasts into the blood circulation. Therefore this study is carried out to study TRACP as a marker for osteoporosis and bone malignancy. A total of 75 subjects were included in this study. They were divided into 3 groups. Group I included 25 diagnosed cases of malignant bone tumors between the age group 20 to 70 years of both sexes. Group II included 25 cases of osteoporosis and group III, the control group, included 25 healthy individuals of the same age groups and sexes. TRACP was estimated in the serum of all the subjects. TRACP levels were highly increased in both the osteoporosis and bone malignancy groups (p<0.001). Therefore TRACP can be considered as a marker for bone resorption in osteoporosis and bone malignancy.",
author = "Rajeshwari and Benedicta D'Souza and Vivian D'Souza",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "5",
journal = "International Journal of Pharma and Bio Sciences",
issn = "0975-6299",
publisher = "International Journal of Pharma and Bio Sciences",
number = "3",

}

Tartarate resistant acid phosphatase as a marker in osteoporosis and bone malignancy. / Rajeshwari; D'Souza, Benedicta; D'Souza, Vivian.

In: International Journal of Pharma and Bio Sciences, Vol. 5, No. 3, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tartarate resistant acid phosphatase as a marker in osteoporosis and bone malignancy

AU - Rajeshwari,

AU - D'Souza, Benedicta

AU - D'Souza, Vivian

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Non prostatic tartarate resistant acid phosphatase(TRACP) is present in bone resorbing osteoclasts. Matrix degradation products together with TRACP are released from the osteoclasts into the blood circulation. Therefore this study is carried out to study TRACP as a marker for osteoporosis and bone malignancy. A total of 75 subjects were included in this study. They were divided into 3 groups. Group I included 25 diagnosed cases of malignant bone tumors between the age group 20 to 70 years of both sexes. Group II included 25 cases of osteoporosis and group III, the control group, included 25 healthy individuals of the same age groups and sexes. TRACP was estimated in the serum of all the subjects. TRACP levels were highly increased in both the osteoporosis and bone malignancy groups (p<0.001). Therefore TRACP can be considered as a marker for bone resorption in osteoporosis and bone malignancy.

AB - Non prostatic tartarate resistant acid phosphatase(TRACP) is present in bone resorbing osteoclasts. Matrix degradation products together with TRACP are released from the osteoclasts into the blood circulation. Therefore this study is carried out to study TRACP as a marker for osteoporosis and bone malignancy. A total of 75 subjects were included in this study. They were divided into 3 groups. Group I included 25 diagnosed cases of malignant bone tumors between the age group 20 to 70 years of both sexes. Group II included 25 cases of osteoporosis and group III, the control group, included 25 healthy individuals of the same age groups and sexes. TRACP was estimated in the serum of all the subjects. TRACP levels were highly increased in both the osteoporosis and bone malignancy groups (p<0.001). Therefore TRACP can be considered as a marker for bone resorption in osteoporosis and bone malignancy.

UR - http://www.scopus.com/inward/record.url?scp=84904892474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904892474&partnerID=8YFLogxK

M3 - Article

VL - 5

JO - International Journal of Pharma and Bio Sciences

JF - International Journal of Pharma and Bio Sciences

SN - 0975-6299

IS - 3

ER -